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bodies, we generated a sensitive assay for MyC on the Erenna platform (Singulex)
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cMyC was quantifiable in 359 patients and compared with cTnT and cTnI measured
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ratiometric comparisons between biomarkers to distinguish clinical instability.
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AT A GLANCE COMMENTARY
Marjot J, et al.
Background
Cardiac myosin–binding protein C (cMyC) is a
protein with cardiac-restricted expression that we
have previously shown appears in the systemic
circulation after acute myocardial injury using a
relatively insensitive assay. This article describes
a high-sensitivity assay for cMyC, which demon-
strates that it can be measured at baseline in almost
all individuals, and in a stable population its
concentration correlates with those for cTnI and
cTnT.
Translational Significance
This article acts as the foundation for a study using
the assay described here in patients presenting with
suspected acute myocardial infarction to compare
the diagnostic and prognostic performances of
cMyC with cTnT and cTnI.
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Acute myocardial infarction (AMI) carries a poor
prognosis that can be improved by timely intervention.
It must therefore be rapidly identified and differentiated
from other causes of chest pain.1 Cardiac necrosis bio-
markers have become crucial in affirming or excluding
AMI in suspected non–ST-elevation acute coronary
syndromes (NSTE-ACSs) and are needed to confirm
the diagnosis in an appropriate clinical context.2
Cardiac troponins (cTns) have emerged as the gold stan-
dard and are incorporated in the universal definition of
AMI.2 However, the cTns have potential drawbacks
and new necrosis biomarkers could prove invaluable.3
The concentration of cTn rises slowly after acute
myocardial injury and does not peak until 16–18 hours
after the onset of chest pain.4 To triage and treat
NSTE-ACS early, it is therefore necessary to heed
cTn concentrations close to the 99th percentile of a
healthy population.5 However, triage is confounded by
the assays’ decreased specificity for myocardial infarc-
tion when used in this way. In addition, diagnostic sensi-
tivity may also be poor because up to 25% of patients
with an eventual diagnosis of AMI are less than this
threshold at presentation.6 Furthermore, although initial
reports suggested that these assays allow more rapid
diagnosis of AMI when the event is defined by a classic
cTn assay,7,8 this advantage is probably lost when
contemporary high-sensitivity assays are also used todefine the index event.9 These drawbacks are acknowl-
edged in the recently updated guidelines for the man-
agement of NSTE-ACSs that adopt cutoffs
substantially less than the 99th percentile to ‘‘rule-
out’’ AMI and substantially greater than the 99th
percentile to ‘‘rule-in’’ AMI.10 This improves sensitivity
and specificity at the expense of increasing the number
of patients with indeterminate troponins requiring
further observation and increased testing.
The sarcomeric protein, cardiac myosin–binding pro-
tein C (C-protein, MYBPC3, cMyBP-C, or cMyC), is
abundant11 and released rapidly into the coronary
effluent.12 Recently, we demonstrated that cMyC accu-
mulates more rapidly in the serum than cTnT; using
timed iatrogenic injury in the setting of alcohol septal
ablation for hypertrophic cardiomyopathy.13 Although
after coronary artery bypass surgery, cMyC disappeared
more rapidly than cTnT.13 However, comparisons were
hindered by an insensitive assay for cMyC (lower limit
of quantification [LLoQ], 80 ng/L), which consequently
could only be quantified after injury had occurred.
Without a sensitive assay for cMyC it is not possible
to compare its diagnostic performance for AMI in sus-
pected NSTE-ACS with those of cTnI and cTnT. The
purpose of this study was to create and validate such a
high-sensitivity assay.MATERIALS AND METHODS
Immunoassay for cMyC. We have previously
described the creation, biophysical selection, and organ
specificity of mouse monoclonal antibodies recognizing
cardiac-restricted epitopes within the N-terminus of
cMyC.13 Two of these antibodies, 1A4 and 3H8, were
used to create a sensitive sandwich immunoassay.
Subsequently, we describe the optimized assay on the
Erenna platform (Merck KGaA, Darmstadt, Germany).
Magnetic microparticles (MPs; Singulex) for capture
were prepared by binding 25 mg of mouse monoclonal
(1A4) per milligram of MPs. The coated MPs were
diluted in assay buffer (Singulex proprietary mix with
custom 450 mM NaCl and 0.5% Triton X-100) to
100 mg/mL. Serum, plasma, or analyte (recombinant
C0C2 domain of cMyC13) was diluted 1:1 in an equal
volume of standard diluent (Singulex) and 100 mL
added per well of a 96-well assay plate. Samples or stan-
dards were then exposed to 100 mL of coated MPs and
agitated for 2 hours at 25C. MPs were retained via a
magnetic bed with unbound material removed in a sin-
gle wash step. Fluorescently labeled mouse monoclonal
(3H8) detection antibody was diluted in assay buffer
(Singulex) to 100 ng/mL. To each well, 20 mL of detec-
tion antibody was added and theMPs agitated for 1 hour
at 25C, retained via a magnetic bed, and then washed 4
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MPs were then transferred to a new plate and all buffer
was aspirated. The MPs were then exposed to 20 mL/
well of elution buffer B (Singulex) for 5 minutes at
25C before transferring to a 384-well plate containing
10 mL/well of neutralization buffer D (Singulex). Fluo-
rescent label was then detected by single molecule
counting using the Erenna system (Singulex) with a
dwell time of 60 s per well. Three signal outputs were
obtained from the Erenna System: detected events
(DEs; low end signal), event photons (low end and
higher end signal), and total photons (high end signal).
Assessing assay performance under serum-free
conditions. Having established a refined set of assay con-
ditions, assayperformancewas assessed using a 12-point
standard curve. Each point consisted of three 3-fold
serially diluted cMyC concentrations to S4, followed
by seven 2-fold serial dilutions to S11. All dilutions
were in standard diluent (Singulex). The curve ranged
from 0.58 to 2000 ng/L (S1–S11) with a 0 ng/L anchor
of unadulterated standard diluent (Singulex). The
lower limit of detection (LoD) was defined as
2.5 3 standard deviation background divided by slope,
and the LLoQ was defined as the lowest point on the
standard curve, which has a coefficient of variation
(CV) #20% where the back interpolated concentration
had a recovery percent bias#20%.14
Assay verification in human serum and
plasma. Interassay and intra-assay series precision was
evaluated in human serum samples that were tested
unadulterated and spiked with 200 ng/L of cMyC. The
samples were diluted 2-fold in standard diluent (1:1
mix) before assaying 6 replicates per sample on Day 1
and 3 replicates per sample on Day 2. Spike recovery
was calculated by subtracting the dilution-corrected
endogenous cMyC concentration from the dilution-
corrected spiked value divided by the expected value.
Dilutional linearity was evaluated by serial dilution of
spiked human plasma. Linearity was calculated by
dividing the dilution-corrected cMyC concentration by
the preceding value, expressed as a percentage.
MyC concentrations in human serum. Between July
2009 and January 2014, 5329 patients were referred to
the Kerckhoff Heart and Thorax Center for elective coro-
nary angiography and providedwritten informed consent
for their participation inblood-basedbiomarker studies as
per institutional ethics board (FF 43/2010). The research
was carried out according to the Code of Ethics of the
World Medical Association (Declaration of Helsinki),
informed consent was obtained, and the author’s
institutional review board has approved the study.
From this population we selected 360 serum samples
based on the absence of obstructive stenoses (,50%) on
invasive coronary angiography and normal (,14 ng/L)high-sensitivity cTnT, renal function, and liver function.
Further criteria used to choose samples were prior mea-
surement of high-sensitivity cTnI and sufficient volume
of stored serum to allow duplicate measurements of
cMyC (.100 mL). cTnT was measured in serum with
the high-sensitivity electrochemiluminescence immu-
noassay (Elecsys Analyzer 2010; Roche Diagnostics,
Mannheim, Germany). For the cTnT assay, the limit
of blank (LoB) 5 3.0 ng/L, LoD 5 5.0 ng/L, and
LLoQ 5 13.0 ng/L. The lowest concentration measur-
able with a CV ,10% for this assay is 13.5 ng/L. The
recommended clinical decision limit (99th percentile)
for rule out of AMI using this assay is 14.0 ng/L.
Concentrations of cTnT less than 3 ng/L (LoB) were
not returned and therefore assigned a value of
1.5 ng/L in all analyses.
cTnI was measured in serum with the high-sensitivity
chemiluminescent immunoassay (ARCHITECT STAT
High Sensitive Troponin; Abbott Laboratories, Abbott
Park, Illinois). For the cTnI assay, LoD 5 1.2 ng/L
and LLoQ5 4.7 ng/L at a CV,10%. The 99th percen-
tile is 15.6 ng/L in women and 34.2 ng/L in men.
Concentrations less than the LoD were returned and
used for comparisons, because all were greater than
the locally determined LoB.
Statistical analysis. The methods used to calculate the
LoDs and LLoQs for MyC are described previously.
The Kolmogorov-Smirnov and Shapiro-Wilk tests
were used to test if cMyC, cTnT, and cTnI concentra-
tions were distributed normally. Spearman’s rank test
was used to assess correlation between the serum
concentrations of each biomarker and to correlate the
concentration of each marker to the continuous demo-
graphic variables of the sample population. Differences
in the distribution of biomarker concentration across
categories of dichotomous variables were examined
using the independent-samples Mann-Whitney test.
Stepwise multiple logistic regression analysis was
used to assess independent association between the vari-
ables and biomarker concentrations. All analyses were
carried out using SPSS v22. Normally distributed data
are presented as the mean 6 standard deviation.
Statistical significance was set at P , 0.05.RESULTS
Analytic sensitivity of the cMyC assay. The 12-point
calibration using recombinant C0C2 domain of cMyC
in standard diluent is shown in Supplementary Table I.
The DE counts are shown for serial dilutions .5. The
linear regression relationship for S5–S12 is DE 5
32.7 3 [cMyC] 1 46.1 (R2 5 0.9995), where [MyC]
is in nanograms per liter. The LLoQ is 1.2 ng/L and
the calculated LoD is 0.4 ng/L.
Table I. Demographics of the patient population
(N 5 359 unless otherwise specified)
Demographic n (%)
Male 146 (40.6%)
Current smoker 131 (36.4%)
BMI $ 30 124 (34.4%) [n 5 358]
Diabetes 39 (10.8%)
Hyperlipidemia 181 (50.3%)
Family history 106 (29.4%)
b-Blocker 182 (50.6%)
Statin 82 (22.8%)
ACE-I/ARB 196 (54.4%)
Aspirin 159 (44.2%)
Digitalis 8 (2.2%)
Aldosterone antagonist 16 (4.4%)
Loop diuretic 56 (15.6%)
Thiazide diuretic 82 (22.8%)
COPD 24 (6.7%)
PVD 10 (2.8%)
Pulmonary HTN 7 (1.9%)
Angina 180 (50.0%)
AF/PPM 32 (8.9%) [n 5 357]
Mean (standard deviation)
Age (y) 60.0 (12.0)
BMI 29.0 (5.6) [n 5 358]
GFR (mL/min/1.73 m2) 100.3 (25.7) [n 5 352]
Creatinine (mg/dL) 0.8 (0.2) [n 5 351]
LVEF (%) 53.7 (12.3) [n 5 189]
Systolic BP (mm Hg) 134.5 (20.9) [n 5 357]
[MyC] (ng/L) 17.6 (16.4)
[TnT] (ng/L) 3.4 (3.2)
[TnI] (ng/L) 3.5 (4.3)
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; AF,
atrial fibrillation;ARB, angiotensin receptor blocker; BMI, bodymass
index; BP, blood pressure; COPD, chronic obstructive pulmonary
disease; GFR, glomerular filtration rate; HTN, hypertension; LVEF,
left ventricular ejection fraction; PPM, permanent pacemaker;
PVD, peripheral vascular disease.
Anginawas defined as any symptom severity using Canadian Car-
diovascular Society grades 1–4. Family history defined as a first de-
gree relative with history of coronary artery disease and/or acute
myocardial infarction and/or percutaneous coronary intervention
and/or coronary artery bypass graft surgery.
Translational Research
20 Marjot et al April 2016Interseries and intraseries precision of the MyC assay in
serum. Sera from 5 individuals were spiked with
200 ng/L of cMyC and subjected to repeated measure-
ment. Six repeated measurements were made on Day 1
and 3 on Day 2. Supplementary Table II shows the CVs
within and between assays. The average CV within
assays was 116 3% and between assays was 136 3%.
Analyte recovery from human serum and
plasma. Supplementary Table III shows analyte
recovery from serum and plasma samples of different
individuals each spiked with 200 ng/L of recombinant
cMyC. The recovery in serum was 108.0 6 6.2%
(excluding lipemic sample, 115.4 6 15.8% with this
sample included) and in plasma 107.1 6 3.7%.
Dilutional linearity was tested using the finalized
assay in plasma (see Supplementary Table IV). The re-
sults showed more than a 16-fold range of dilutions in
plasma from 8 individuals, and linearity was 1016 7%.
Comparison of cMyC, cTnT, and cTnI concentrations in
stable patients. The demographics of the population
cohort used to compare biomarker concentrations are
shown in Table I.
Three hundred sixty serum samples with [cTnT]
,14 ng/L were analyzed. In one of these samples,
cMyC was less than the LLoQ. Our subsequent analysis
was of the 359 patients with an evaluable cMyC.Of these
274 patients had cTnT (,5 ng/L), and 52 patients cTnI
(,1.2 ng/L), concentrations less than the LoD. The re-
sulting truncation of the leftmost portion of the
concentration-frequency distribution is therefore evident
for cTnTand cTnI but not for cMyC (see Fig 1). None of
the concentration-frequency histograms were normally
distributed. The summary statistics describing their dis-
tribution are inset in the respective panels of Fig 1. In ab-
solute terms cMyC is approximately 5 times more
abundant than either cTnI or cTnT, as previously noted.13
Our cMyC assay therefore has sensitivity at least as good
as the current commercial assays for cTnTand cTnI. The
question is whether the concentrations of cMyC are
related to those of the cTns?
Fig 2 shows the relationships between the biomarkers.
Serum concentrations of cMyC, cTnT, and cTnI are all
positively correlated with one another with the strongest
association between [MyC] and [TnI].
Because the biomarkers are co-correlated we looked
at the demographic variables known to influence
[cTnT] and [cTnI] to determine if they similarly influ-
ence cMyC. The continuous variables are shown in
Table II as correlation coefficients and the discontin-
uous variables in Table III as differences in mean
biomarker concentration between those with and
without the demographic feature. Generally, each of
the biomarkers segregates similarly and concentrations
are greater in patients with comorbidities.A stepwise multiple logistic regression analysis was
performed to determine which independent variables
statistically significantly predicted the serum biomarker
concentrations, independently of other covariates
(Table IV). In this analysis, age, gender, creatinine, pul-
monary hypertension, and use of statins, loop diuretics,
and b-blockers all statistically predicted cMyC
(P , 0.05), R2 5 0.198, n 5 346. Because left ventric-
ular ejection fraction (LVEF) was only known for 189
samples, LVEF was omitted from the analysis to pre-
serve sample size and statistical power. With LVEF
included in the analysis, only creatinine, LVEF,
and age significantly predicted cMyC (P , 0.01),
Fig 1. Distribution of cMyC, cTnI, and cTnT concentrations among
359 patients referred for elective coronary angiography with a cTnT
,14 ng/L. To validate the cMyC assay described in Supplementary
Translational Research
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same model was applied to cTnI and cTnT, excluding
LVEF as a variable. cTnI was significantly predicted
by age, gender, use of angiotensin-converting enzyme
inhibitor and, or angiotensin receptor blockers (ACE-
I/ARBs), statins, and loop diuretics, and irregular or
paced cardiac rhythm (P , 0.05), R2 5 0.153,
n 5 346. cTnT was significantly predicted by age,
gender, family history of heart disease (see Table I for
definition), pulmonary hypertension, angina, diabetes,
and use of ACE-I/ARBs, aldosterone antagonists and
statins (P , 0.05), R2 5 0.299, n 5 346. A distinctive
feature of MyC was its association with b-blocker use.
DISCUSSION
We have developed a high-sensitivity assay to mea-
sure cMyC in serum or plasma. In 360 stable patients
with a cTnT ,14 ng/L, cMyC was quantifiable in 359
patients, a sensitivity much greater than that achieved
with cTnT (4 patients with greater than
LLoQ 5 13.0 ng/L) or cTnI (78 patients with greater
than LLoQ 5 4.7 ng/L). cMyC is the first cardiac-
specific marker of injury to be described since cTnT
and cTnI. Generally, concentrations of cMyC were
highly correlated with those of cTnI and cTnT and
were influenced by the same demographic features
including gender, age, renal function, left ventricular
function, medication, and heart rhythm.
The close correlation between cMyC and cTnT/cTnI
is surprising because their locations within the sarco-
mere differ.15 cTnT and cTnI are adjacent proteins on
the thin filament (actin), whereas cMyC, as its name
suggests, is predominantly bound to the thick filament
(myosin). The precise reason for the appearance of car-
diac sarcomeric proteins in the peripheral blood of
healthy individuals is not known. However, because
none of these proteins are actively exported, and anTables I–IV we examined a stable patient cohort without acute
myocardial injury. Also excluding acute myocardial injury by their
mode of presentation, only patients with a [cTnT] less than the 99th
percentile of a healthy ‘‘normal’’ population (14 ng/L) were
included. All patients had a [cMyC] . LLoQ. Unfortunately, 274
patients (more than half the cohort) had a [cTnT] ,5.0 ng/L, the
LoD of the assay. Sera with a [cTnT] ,3.0 ng/L (LoB) were
assigned a value of 1.5 ng/L. Similarly, 52 patients had a [TnI]
,1.2 ng/L, the LoD of the assay. For TnI the sera retained the value
assigned by the assay because values were greater than the locally
determined LoB. The differential sensitivities of the assay are the
cause for artifactual distortion of low concentration portion of the
histograms. Inset in each panel are the descriptors of the biomarker
concentration distribution. None of the biomarkers are normally
distributed. cMyC, cardiac myosin–binding protein C; cTn, cardiac
troponin; IQR, interquartile range; LLoQ, lower limit of
quantification; LoD, lower limit of detection.
Fig 2. Relationships between cMyC, cTnI, and cTnT.All 3 biomarkers
significantly correlate with one another. The correlation coefficient
(Spearman’s Rho) is shown on the upper right quadrant. **P , 0.01.
cMyC, cardiac myosin–binding protein C; cTn, cardiac troponin.
Table II. Correlation coefficients (Spearman’s Rho)
between serum concentration of cTnI, cTnT, and
cMyC and continuous variables in the sample
population
Demographic variable cTnI cTnT cMyC
Age 0.336* 0.448* 0.385*
GFR 20.224* 20.256* 20.288*
Creatinine 0.197* 0.220* 0.284*
LVEF 20.208* 20.169† 20.218*
Systolic BP 0.116† 0.176* 0.134†
BMI 0.069 0.068 0.011
Abbreviations: BMI, body mass index; BP, blood pressure; cMyC,
cardiac myosin–binding protein C; cTn, cardiac troponin; GFR,
glomerular filtration rate; LVEF, left ventricular ejection fraction.
*P , 0.01.
†P , 0.05.
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their appearance in the circulation most likely repre-
sents ‘‘stable’’ slow attrition and dissolution of cardiacmyocytes. In such a scenario, the release rates of all
cardiac-specific proteins are likely to co-correlate
because they document the same fundamental process.
Furthermore, the rapidity of this process is likely to be
influenced by traditional cardiac risk factors explaining
the correlation with gender and age, whereas the pro-
gression of this process will be documented by other
measures of cardiac injury explaining the correlation
with left ventricular function, pulmonary artery hyper-
tension, and medication. The correlation with renal
function is likely to have more complex explanations
including the renal excretion of immunoreactive
N-terminal fragments of cMyC, cTnI, and cTnT; the
accumulation of waste products that increase the rate
of myocyte attrition; or common factors that cause
cellular injury to both the heart and the kidney.
Although, the factors affecting cTnI, cTnT, and cMyC
are broadly very similar (see Tables II and III), serum
cMyC concentration is particularly affected by
b-blocker prescription with an average 6.5 ng/L
higher concentration in those taking medications of
this class (a relationship that continues to be
significant after multiple regression analysis). A
possible explanation for this exceptional dichotomy
between the biomarkers may relate to protein kinase
A–dependent phosphorylation of critical serine
residues within the M domain of cMyC.17 When phos-
phorylated, these residues more effectively guard a cal-
pain cleavage site within cMyC.15,17 Cleavage at this
site releases a 40 kDa N-terminal fragment, the
dominant fragment we observed in serum of patients
with AMI.12,13,18 Interestingly this fragment may act
as a ‘‘poison peptide’’ causing cardiac dysfunction.15
Thus, unlike cTnI and cTnT, cMyC may not just be a
bystander biomarker of cardiac injury, but lie on the
causal pathway leading to myocardial disease.
Table III. Mean biomarker concentration in the each category of dichotomous population variable
Demographic variable
Mean concentration in each group (difference in mean concentrations)
cTnI (ng/L) cTnT (ng/L) cMyC (ng/L)
Nonmodifiable risk factors
Family history vs no family history 3.27 vs 3.66 (0.38*) 3.37 vs 3.38 (0.01) 15.0 vs 18.7 (3.71*)
Female vs male 3.22 vs 3.69 (0.47) 3.27 vs 3.49 (0.22) 16.3 vs 19.4 (3.15)
Lifestyle
Current smoker vs nonsmoker 3.12 vs 3.79 (0.67) 2.89 vs 3.66 (0.78*) 16.0 vs 18.5 (2.52)
BMI $ 30 vs BMI , 30 4.07 vs 3.25 (0.82) 3.48 vs 3.30 (0.18) 16.2 vs 18.2 (2.04)
Comorbidities
Pulmonary HTN vs no pulmonary HTN 8.84 vs 3.44 (5.41†) 8.61 vs 3.28 (5.33†) 44.4 vs 17.0 (27.32†)
AF/PPM vs sinus rhythm 5.88 vs 3.27 (2.61†) 4.92 vs 3.20 (1.71†) 27.0 vs 16.5 (10.55†)
Diabetes vs no diabetes 3.59 vs 3.54 (0.05) 4.21 vs 3.28 (0.93) 19.7 vs 17.3 (2.38)
Hyperlipidemia vs no hyperlipidemia 3.19 vs 3.90 (0.71) 3.07 vs 3.69 (0.62) 16.6 vs 18.6 (1.94)
COPD vs not COPD 3.98 vs 3.51 (0.47) 3.88 vs 3.34 (0.53) 17.3 vs 17.6 (0.38)
PVD vs no PVD 4.19 vs 3.53 (0.67) 3.37 vs 3.38 (0.01) 20.9 vs 17.5 (3.44)
Angina vs no angina 3.14 vs 3.95 (0.80) 3.07 vs 3.69 (0.62) 16.0 vs 19.2 (3.17)
Pharmacotherapy
b-blocker vs no b-blocker 3.71 vs 3.37 (0.34) 3.52 vs 3.24 (0.28) 20.8 vs 14.3 (6.51†)
ACE-I/ARB vs no ACE-I/ARB 4.26 vs 2.68 (1.58†) 3.98 vs 2.66 (1.32†) 20.2 vs 14.5 (5.75†)
Aspirin vs no aspirin 3.13 vs 3.87 (0.75†) 2.98 vs 3.70 (0.72*) 15.9 vs 19.0 (3.09*)
Digitalis vs no digitalis 5.16 vs 3.51 (1.66) 5.60 vs 3.33 (2.27*) 28.1 vs 17.4 (10.77†)
Aldosterone antagonist vs no aldosterone antagonist 5.37 vs 3.46 (1.91†) 5.86 vs 3.26 (2.59†) 30.5 vs 17.0 (13.52†)
Loop diuretic vs no loop diuretic 5.61 vs 3.16 (2.45†) 4.93 vs 3.09 (1.83†) 26.9 vs 15.9 (10.98†)
Thiazide diuretics vs no thiazide diuretic 4.56 vs 3.24 (1.32†) 4.39 vs 3.08 (1.30†) 23.1 vs 16.0 (7.16†)
Statin vs no statin 2.82 vs 3.76 (0.94*) 2.70 vs 3.58 (0.88) 15.0 vs 18.3 (3.32)
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index;
cMyC, cardiac myosin–binding protein C; COPD, chronic obstructive pulmonary disease; cTn, cardiac troponin; HTN, hypertension; PPM, per-
manent pacemaker; PVD, peripheral vascular disease.
In brackets is the difference in mean biomarker concentrations between the 2 categories.
*P , 0.05.
†P , 0.01.
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diagnostic biomarker of acute myocardial injury than
cTnT or cTnI. On the basis of our previous findings
with a much less sensitive assay, after iatrogenic
myocardial injury cMyC is released and cleared more
rapidly from the peripheral circulation than cTnT.13
The findings presented here are necessary stepping
stones toward a large study of patients with suspected
NSTE-ACS where the diagnostic utility of cMyC can
be compared with cTnI and cTnT. Nonetheless, it is
tempting to speculate how our present study will have
impact on the diagnostic performance of cMyC in this
clinical scenario. We had hoped cMyC concentrations
would not be influenced by age, gender, renal function,
and other cardiac risk factors. Our results clearly
suggest that baseline cMyC concentrations will be
higher in those at risk of an NSTE-ACS than in healthy
controls. Thus, it is likely cMyC will have the same in-
adequacy as cTnI and cTnT in differentiating chronic
increases in biomarker concentration from the minor in-
creases associated with the start of an acute myocardial
injury event. However, if our findings of faster MyC
release in iatrogenic injury hold true with spontaneous
myocardial injury, then the close correlation betweenMyC and cTnI/cTnT could become uncoupled as the
biomarkers rise asymmetrically during acute injury.
On the other hand, the abundance, ease of measurement,
and correlation of cMyC with comorbidities may pro-
vide an advantage in the monitoring of chronic disease.
One of the major limitations of the present study is
that the study population was not healthy, and we there-
fore cannot estimate the 99th percentile concentration
for cMyC. In choosing the population to validate our
novel assay, we thought it more important to have a
complete description of their demographics with the
availability of other laboratory measures, including
contemporary high-sensitivity cTnI and cTnT. This
choice was consolidated by the lack of guidance on
how rigorously to exclude covert cardiac disease in a
healthy cohort and the influence this uncertainty has
on the 99th percentile returned by that particular unique
healthy cohort. Finally, we reasoned that the patient
population we studied is more representative of those
that will attend with a suspected NTSE-ACS event
than a healthy younger cohort without cardiac risk fac-
tors. Nonetheless, the 99th percentiles returned in our
population closely match those defined in healthy con-
trol populations for the assays we used for TnT (13 vs
Table IV. Unstandardized coefficients (B) for those
variables which independently predict biomarker
concentration in stepwise linear multiple regression
analysis (n 5 346)
Demographic variable
Unstandardized
coefficients (B) Significance
MyC
Creatinine 10.689 0.024
Age 0.286 0.000
Female 25.128 0.004
Loop diuretic 6.889 0.002
Statin 25.510 0.003
B-blocker 4.436 0.009
Pulmonary hypertension 14.813 0.024
TnI
Age 0.067 0.000
Female 21.879 0.000
ACE-I/ARB 1.136 0.014
Loop diuretic 1.639 0.010
Statin 21.377 0.008
AF/PPM 1.572 0.047
TnT
Age 0.114 0.000
Female 21.012 0.001
ACE-I/ARB 0.825 0.007
Statin 21.477 0.000
Aldosterone antagonist 2.001 0.007
Family history 0.820 0.013
Pulmonary hypertension 4.771 0.000
Angina 20.603 0.040
Diabetes 0.934 0.047
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; AF,
atrial fibrillation; ARB, angiotensin receptor blocker; MyC, myosin-
binding protein C; PPM, permanent pacemaker.
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tively).
A further limitation is that the Erenna platform on
which the cMyC assay is performed is currently only
available for research purposes and cannot provide the
flexibility or turn-around times required for clinical
use. These deficiencies could be addressed by migration
to another platform or through the development of the
Erenna platform.
Another ‘‘high-sensitivity’’ assay for cMyC has been
described recently.19 However, this assay has a sensi-
tivity of 2–3 orders of magnitude lower than ours and
reports a mean difference in cMyC concentration
between controls and patients with AMI of approxi-
mately 3-fold (1.5 mg/L increasing to 5 mg/L).19
These concentrations are difficult to reconcile with
those presented here or previously.13CONCLUSIONS
We have developed and validated a sensitive assay for
cMyC, which for the first time allows this cardiac-specific marker of myocardial injury to be quantified
in ambulatory patients. The diagnostic performance of
this assay is yet to be compared with cTnI and cTnT
in the setting of NSTE-ACS.ACKNOWLEDGMENTS
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25.e1 Marjot et al April 2016SUPPLEMENTARY DATASupplementary Table I. Analytic performance of the cMy
Standard Expected [cMyC], ng/L n Mean DE
S1 2000 3
S2 666.67 3
S3 222.22 3
S4 74.07 3
S5 37.04 3 1254
S6 18.52 3 665.33
S7 9.26 3 344.33
S8 4.63 2 189
S9 2.32 3 106.33
S10 1.16 2 89.5
S11 0.58 3 74
S12 0 3 51
Abbreviations: cMyC, cardiac myosin–binding protein C; CV, coefficient oC assay under serum-free conditions
Observed [cMyC], ng/L %CV Recovery
1998.55 3% 100%
732.07 4% 110%
227.84 12% 103%
68.72 8% 93%
36.86 3% 100%
19.63 4% 106%
9.79 4% 106%
4.7 23% 102%
1.85 5% 80%
1.27 13% 110%
0.75 20% 129%
ND — —
f variation; DE, detected event; ND, not determined.
Supplementary Table II. Analytic precision of the cMyC assay using serum from 5 individuals with (1200) andwithout the addition of a 200 ng/L spike of
recombinant cMyC
ID
Day 1 Intraseries Day 2 Interseries
1 2 3 4 5 6 Mean SD %CV 1 2 3 Mean SD %CV
1 4.77 6.22 4.54 4.6 4.54 4.77 4.91 0.65 13% 4.97 — 6.35 5.09 0.75 15%
1 1 200 249.2 228.4 — 241.6 248.4 286.8 250.87 21.74 9% 223.9 234.1 214.7 240.88 22.1 9%
2 20.66 19.39 14.71 18.03 15.89 17.36 17.67 2.19 12% 24.79 20.82 26.69 19.81 3.95 20%
2 1 200 322.9 291.5 304.6 290.5 361 382 325.43 38.15 12% 274.1 311.4 246.9 309.44 41.8 14%
3 71.53 70.13 70.6 66.66 59.34 62.43 66.78 4.95 7% 64.44 55.36 51.45 63.55 7.07 11%
3 1 200 252 241.9 276.5 264.6 271.4 342.4 274.79 35.47 13% 252 261.3 229 265.68 32.3 12%
4 13.55 14.76 13.65 13.13 11.28 10.23 12.77 1.68 13% 16.97 17.07 12.76 13.71 2.3 17%
4 1 200 216.5 199.2 249.8 273.8 224.1 236.6 233.32 26.26 11% 197.5 203.4 220.4 224.57 25.3 11%
5 17.74 17.92 16.76 15.34 11.49 16.13 15.9 2.37 15% 17.66 17.62 13.49 16.02 2.23 14%
5 1 200 232.6 255.3 258.8 228 252.9 254.9 247.07 13.19 5% 187.8 204.8 216.2 232.36 25.4 11%
Abbreviations: cMyC, cardiac myosin–binding protein C; CV, coefficient of variation; DE, detected event.
All values are in nanograms per liter unless stated otherwise. The serum of individual number 2 was lipemic.
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Supplementary Table IV. Dilutional linearity of human plasma spiked with 200 ng/L of cMyC
Sample n Dilution factor Mean [cMyBP-C], pg/mL SD %CV
Dilution corrected
[cMyBP-C], ng/L Dilutional linearity
1 3 2 206.14 3.18 2% 412.28
1 3 4 105.42 7.16 7% 421.68 102%
1 3 8 49.05 2.09 4% 392.43 93%
1 3 16 26.83 1.72 6% 429.25 109%
2 3 2 228.05 9.71 4% 456.09
2 3 4 123.61 4.54 4% 494.43 108%
2 3 8 54.84 4.57 8% 438.72 89%
2 3 16 28.34 0.15 1% 453.43 103%
3 3 2 221.06 7.5 3% 442.12
3 3 4 114.14 2.55 2% 456.56 103%
3 3 8 54.71 3.09 6% 437.67 96%
3 3 16 29.55 1.48 5% 472.87 108%
4 3 2 212.16 15.7 7% 424.33
4 3 4 116.07 1.48 1% 464.26 109%
4 3 8 53.23 1.94 4% 425.81 92%
4 3 16 28.98 1.19 4% 463.61 109%
5 3 2 227.78 10.4 5% 455.56
5 3 4 108.27 6.32 6% 433.06 95%
5 3 8 51.02 1.67 3% 408.2 94%
5 3 16 27.81 0.94 3% 445.03 109%
6 3 2 212.02 16.3 8% 424.03
6 3 4 102.62 3.97 4% 410.47 97%
6 3 8 48.11 1.39 3% 384.84 94%
6 3 16 27.04 0.82 3% 432.69 112%
7 3 2 212.46 2.43 1% 424.91
7 3 4 101.82 2.19 2% 407.28 96%
7 3 8 46.98 1.31 3% 375.83 92%
7 3 16 26.4 1.33 5% 422.35 112%
8 3 2 230.68 11.2 5% 461.36
8 3 4 103.66 5.41 5% 414.65 90%
8 3 8 50.05 2.68 5% 400.37 97%
8 3 16 28 1.47 5% 447.96 112%
Abbreviations: cMyC, cardiac myosin–binding protein C; CV, coefficient of variation; SD, standard deviation.
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Supplementary Table V. Results of stepwise multiple linear regression analysis for each biomarker, excluding
LVEF as an independent variable (n 5 346)
Demographic variable
Unstandardized coefficients Standardized coefficients
t Significance
95.0% Confidence interval for B
B Standard error Beta Lower bound Upper bound
MyC
Creatinine 10.689 4.714 0.128 2.268 0.024 1.418 19.961
Age 0.286 0.068 0.218 4.197 0.000 0.152 0.420
Female 25.128 1.774 20.163 22.890 0.004 28.618 21.638
Loop diuretic 6.889 2.200 0.160 3.132 0.002 2.562 11.216
Statin 25.510 1.869 20.149 22.948 0.003 29.187 21.834
b-Blocker 4.436 1.679 0.142 2.641 0.009 1.132 7.739
Pulmonary HTN 14.813 6.547 0.113 2.263 0.024 1.935 27.690
TnI
Age 0.067 0.019 0.186 3.552 0.000 0.030 0.103
Female 21.879 0.444 20.218 24.235 0.000 22.751 21.006
ACE-I/ARB 1.136 0.461 0.132 2.467 0.014 0.230 2.042
Loop diuretic 1.639 0.633 0.139 2.589 0.010 0.394 2.885
Statin 21.377 0.514 20.136 22.680 0.008 22.388 20.367
AF/PPM 1.572 0.790 0.105 1.990 0.047 0.018 3.126
TnT
Age 0.114 0.013 0.431 8.889 0.000 0.088 0.139
Female 21.012 0.300 20.160 23.373 0.001 21.602 20.422
Family history 0.820 0.326 0.119 2.510 0.013 0.177 1.462
Pulmonary HTN 4.771 1.223 0.180 3.901 0.000 2.365 7.176
Angina 20.603 0.293 20.096 22.059 0.040 21.179 20.027
Diabetes 0.934 0.468 0.093 1.995 0.047 0.013 1.855
Statin 21.477 0.348 20.198 24.244 0.000 22.162 20.793
ACE-I/ARB 0.825 0.302 0.130 2.727 0.007 0.230 1.420
Aldosterone antagonists 2.001 0.732 0.129 2.735 0.007 0.562 3.441
Abbreviations: ACE, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; HTN, hypertension; LVEF,
left ventricular ejection fraction; MyC, myosin-binding protein C; PPM, permanent pacemaker.
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Supplementary Table VI. Results of stepwise multiple linear regression analysis for each biomarker, including
LVEF as an independent variable (n 5 183)
Demographic variable
Unstandardized coefficients Standardized coefficients
t Significance
95.0% Confidence interval for B
B Standard error Beta Lower bound Upper bound
MyC
Creatinine 23.452 6.034 0.261 3.886 0.000 11.545 35.360
LVEF 20.366 0.094 20.263 23.915 0.000 20.551 20.182
Age 0.339 0.089 0.255 3.791 0.000 0.163 0.516
TnI
Female 22.772 0.687 20.280 24.035 0.000 24.127 21.416
LVEF 20.106 0.028 20.257 23.744 0.000 20.162 20.050
Age 0.097 0.027 0.246 3.528 0.001 0.043 0.151
TnT
Age 0.113 0.017 0.431 6.533 0.000 0.079 0.147
LVEF 20.059 0.017 20.216 23.398 0.001 20.094 20.025
Pulmonary HTN 5.214 1.262 0.255 4.131 0.000 2.723 7.705
Statin 21.797 0.531 20.212 23.382 0.001 22.845 20.748
Female 21.401 0.417 20.213 23.361 0.001 22.224 20.578
Family history 1.130 0.479 0.149 2.361 0.019 0.185 2.074
ACE-I/ARB 1.036 0.440 0.150 2.358 0.020 0.169 1.904
Abbreviations: ACE, angiotensin-converting enzyme inhibitor;ARB, angiotensin receptor blocker; HTN, hypertension; LVEF, left ventricular ejec-
tion fraction; MyC, myosin-binding protein C.
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